Fulgent Genetics Inc. Reports Quarterly Earnings Estimate

Fulgent Genetics, Inc., a biotechnology company based in Temple City, United States, has recently disclosed its quarterly earnings estimate. The company, which specializes in health care, offers genetic testing services aimed at providing physicians with crucial clinical information.

Over the past year, Fulgent Genetics’ stock price has experienced significant fluctuations. The stock reached a 52-week high of $25.11 USD on August 1, 2024. However, it also hit a 52-week low of $14.57 USD on March 3, 2025. As of April 27, 2025, the stock price is $18.88 USD, reflecting a moderate level of volatility.

The company operates within the Health Care sector, specifically under the Health Care Providers & Services industry. Fulgent Genetics is listed on the Nasdaq exchange, with its financials reported in USD. The company’s market capitalization stands at $587.68 million USD. Despite its active presence in the market, the company’s price-to-earnings ratio is currently at -13.45, indicating challenges in profitability.

Fulgent Genetics continues to focus on its core mission of delivering advanced genetic testing solutions to support healthcare providers in making informed clinical decisions.